The data indicated that IL-6 might be a potential diagnostic biomarker that could be used to separate colorectal cancer patients from healthy subjects, reporting an AUC of 0.82 in a ROC analysis (95% CI 0.75–0.89). This evidence concerns the gene IL6 and colorectal cancer.